DADC
DNLI icon

D.A. Davidson & Co’s Denali Therapeutics DNLI Stock Holding History

D.A. Davidson & Co’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Sell
87,741
-22,494
-20% -$462K 0.01% 708
2026
Q1 		$2.12M Buy
110,235
+3,302
+3% +$65.7K 0.01% 683
2025
Q4 		$1.77M Buy
+106,933
New +$1.8M 0.01% 706
2018
Q4 		– Sell
-15,833
Closed -$344K – 1111
2018
Q3 		$344K Sell
15,833
-5,017
-24% -$83K 0.01% 857
2018
Q2 		$318K Buy
20,850
+10,850
+109% +$204K 0.01% 850
2018
Q1 		$197K Buy
+10,000
New +$206K ﹤0.01% 1012

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.A. Davidson & Co's DNLI Position: Q2 2026 in Review

D.A. Davidson & Co reduced its Denali Therapeutics (DNLI) stake by 20% in Q2 2026, selling an estimated $462K and leaving 87,741 shares worth $2.26M. The position accounts for 0.01% of the portfolio, ranked #708.

D.A. Davidson & Co first reported a position in DNLI in Q1 2018 and has held it in 6 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • D.A. Davidson & Co held 87,741 shares of Denali Therapeutics worth $2.26M as of Q2 2026.
  • D.A. Davidson & Co sold 22,494 Denali Therapeutics shares in Q2 2026, an estimated $462K.
  • Denali Therapeutics made up 0.01% of D.A. Davidson & Co's portfolio in Q2 2026, its #708 holding.
  • D.A. Davidson & Co first reported a position in Denali Therapeutics in Q1 2018 and has held it in 6 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.